Results 21 to 30 of about 305 (130)

An animal study on the effect of topically administered ambroxol for dry eye

Frontiers in Bioscience-Landmark, 2022
Objective: To evaluate the effect of 0.2% ambroxol eye drop on tear secretion and corneal healing on a rabbit dry eye model, and to delineate potential underlying mechanisms.
Zixuan Wang, Li Yu, Shaochong Zhang, Zhenhan Wang, Mingwu Wang   +4 more
doaj   +1 more source

Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty

Frontiers in Medicine, 2023
BackgroundAmbroxol is a widely used mucoactive drug in sputum clearance of respiratory diseases taken orally and by injection. However, there is a paucity of evidence for inhaled ambroxol in sputum clearance.MethodsThis study performed a multicenter ...
Zeguang Zheng, Kai Yang, Ni Liu, Xiuhua Fu, Huijie He, Hong Chen, Peijun Xu, Jing Wang, Maofeng Liu, Yuling Tang, Fengzi Zhao, Shufeng Xu, Xiaowei Yu, Jichang Han, Bo Yuan, Bin Jia, Guifen Pang, Yantong Shi, Min Kuang, Haiyan Shao, Hao Xiong, Jia He, Yuanyuan Pan, Rongchang Chen   +23 more
doaj   +1 more source

Spectrophotometric Determination of Ambroxol by Chromotropic acid disodium salt dihydrate [PDF]

Journal of Bioscience and Applied Research
An easy and prompt spectrophotometric method was proposed for the limitation of the drug Ambroxol substance containing the amine group by the organic reagent (4,5-Dihydroxynaphthalene-2,7-disulfonic acid disodium salt dihydrate).
Riyadh R. Al - Araji, Abd Ali Abd Al-Hussein Shalan Al-Mushhdi   +1 more
doaj   +1 more source

Promising Effect of High Dose Ambroxol Treatment on Neurocognition and Motor Development in a Patient With Neuropathic Gaucher Disease 2

Frontiers in Neurology, 2022
Gaucher Disease (GD) 2 is a rare inherited lysosomal disorder. Early-onset and rapid progression of neurovisceral symptoms lead to fatal outcome in early childhood. Treatment is symptomatic, a curative therapy is currently not available. This prospective
Charlotte Aries, Benjamin Lohmöller, Stephan Tiede, Stephan Tiede, Karolin Täuber, Karolin Täuber, Guido Hartmann, Cornelia Rudolph, Nicole Muschol   +8 more
doaj   +1 more source

Biological and antimicrobial properties of the association Ambroxol and a water-soluble viscous liquid as a vehicle for a tricalcium silicate-based sealer

Journal of Materials Science: Materials in Medicine, 2021
This study aimed to investigate the antimicrobial and biological properties of Ambroxol associated with glycerin (GLI), propylene glycol (PG), and polyethylene glycol (PEG) as a possible vehicle for an experimental tricalcium silicate sealer, with the ...
Índia Olinta de Azevedo Queiroz, Thiago Machado, Camila Carneiro Alves, Victor Gustavo Balera Brito, Bruno Carvalho de Vasconcelos, João Eduardo Gomes-Filho, Edilson Ervolino, Sandra Helena Penha de Oliveira, Marco Antonio Hungaro Duarte   +8 more
doaj   +1 more source

Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers

Pulmonary Therapy, 2020
Plain Language Summary Ambroxol is used to relieve the symptoms of respiratory conditions in which abnormal mucus secretion is a problem, including the common cold, acute and chronic bronchitis, and chronic obstructive pulmonary disease.
Celine Ollier, Ulrike Sent, Margarida Mesquita, Martin C. Michel   +3 more
doaj   +1 more source

Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells

Neurobiology of Disease, 2015
Heterozygous mutations in GBA1 gene, encoding for lysosomal enzyme glucocerebrosidase (GCase), are a major risk factor for sporadic Parkinson's disease (PD).
Giulia Ambrosi, Cristina Ghezzi, Roberta Zangaglia, Giovanna Levandis, Claudio Pacchetti, Fabio Blandini   +5 more
doaj   +1 more source

Development and Validation of Salbutamol, Bromhexine, Ambroxol and Guauaifenesin Determination in Human Plasma by HPLC-MS/MS Method

Разработка и регистрация лекарственных средств, 2019
Introduction. Multicomponent oral drugs containing salbutamol, bromhexine, ambroxol and guaifenesin have a mucolytic, expectorant and bronchodilator effect.
T. N. Komarov, D. S. Bogdanova, O. A. Miskiv, A. V. Aleshina, I. E. Shohin, Yu. V. Medvedev, N. S. Bagaeva, I. M. Korenskaya   +7 more
doaj   +1 more source

Therapy in Bronchopulmonary Diseases Associated with Increased Secretion of Viscous Sputum and Impaired Mucus Transport

Zdorovʹe Rebenka, 2015
The article deals with the problem of cough in bronchopulmonary diseases, in particular, the attention is paid to cough with increased secretion of viscous sputum, i.e., productive cough.
Yu.V. Marushko, M.H. Hrachova
doaj   +1 more source

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ambroxol Hard-Boiled Lozenges in Patients with Acute Pharyngitis

Pulmonary Therapy, 2019
Introduction The aim of this study was to evaluate the efficacy and safety of a new hard-boiled lozenge formulation containing ambroxol 20 mg versus placebo for the relief of sore throat in patients with acute pharyngitis.
Rita Sousa, Deepak R. Lakha, Sandrine Brette, Simon Hitier   +3 more
doaj   +1 more source